Patients with a history of retinopathy should undergo ophthalmologic evaluation before initiating therapy and be monitored during treatment, as determined by the prescribing provider
Unlike traditional weight-loss methods, it works by targeting both GLP-1 and GIP receptors, helping regulate appetite, improve blood sugar control, and enhance metabolism
The dosing protocol involves a gradual titration over several months, starting low to minimize gastrointestinal side effects and increasing to the target maintenance dose
The solution involves three options: Option 1: Inform your doctor
Sources Eli Lilly and Company: Tirzepatide for the Treatment of Obesity The New England Journal of Medicine: Tirzepatide Once Weekly for the Treatment of Obesity Diabetes Care: Efficacy and Safety of Tirzepatide for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis American Diabetes Association: Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes Obesity (Silver Spring): Predictors of Weight Loss Response with Once-Weekly Semaglutide Treatment NPR: Report on Compounded Tirzepatide and Legal Issues Important Medical Information and Disclaimers Important Current Status Update : On March 19, 2025, the FDA ended enforcement discretion for compounded tirzepatide